Tag results:

MYC

Reprogramming of One Human Induced Pluripotent Stem Cell Line from Healthy Donor

[Stem Cell Research] The authors generated an iPSC line from the skin fibroblasts collected from a healthy 50-year old male donor. This model that could be used to model physiological processes and screen drug validation in vitro.

Focal Disruption of DNA Methylation Dynamics at Enhancers in IDH-Mutant AML Cells

[Leukemia] Recurrent mutations in IDH1 or IDH2 in acute myeloid leukemia (AML) are associated with increased DNA methylation. Scientists analyzed whole-genome bisulfite sequencing data from 15 primary AML samples with IDH1 or IDH2 mutations,

Low NCOR2 Levels in Multiple Myeloma Patients Drive Multidrug Resistance via MYC Upregulation

[Blood Cancer Journal] To define the role of NCOR2 in multiple myeloma, the authors created NCOR2 knockout human myeloma cell lines and demonstrated that NCOR2 knockout led to high MYC expression.

Elevated ATGL in Colon Cancer Cells and Cancer Stem Cells Promotes Metabolic and Tumorigenic Reprogramming Reinforced by Obesity

[Oncogenesis] Elevated ATGL levels in human colon cancer cells relative to non-transformed were augmented by an obesity mediator, oleic acid.

MiRNA-Mediated Control of Exogenous OCT4 during Mesenchymal-Epithelial Transition Increases Measles Vector Reprogramming Efficiency

[Molecular Therapy-Methods & Clinical Development] Using Measles reprogramming vectors, researchers presented microRNA-targeting of exogenous OCT4 to shut down its expression during the mesenchymal to the epithelial transition phase of reprogramming.

Phase Ib Study of the BET Protein Inhibitor RO6870810 with Venetoclax and Rituximab in Patients with Diffuse Large B Cell Lymphoma

[Blood Advances] Researchers reported results of a phase Ib dose-escalation study of the novel, subcutaneous BET inhibitor RO6870810 combined with the BCL-2 inhibitor venetoclax, and rituximab, in recurrent/refractory diffuse large B cell lymphoma.

Popular